Deniz YÜCE, Şuayib YALÇIN, Gürkan GÜNER, Deniz Can GÜVEN, https://orcid.org/0000-0003-3540-0701, Mustafa ERMAN, Taha Koray ŞAHİN, Fadime Sinem ARDIÇ

The platelet to lymphocyte ratio predicts overall survival better than the neutrophil to lymphocyte ratio in metastatic renal cell carcinoma

Background/aim: The prognostic values of systemic inflammatory markers, neutrophil to lymphocyte ratio (NLR), and platelet to lymphocyte ratio (PLR) on overall survival (OS) of metastatic renal cell carcinoma patients (mRCC) treated with tyrosine kinase inhibitors (TKI) remain unclear. Thus, the present study aimed to investigate the prognostic impact of these markers on OS of mRCC patients. Materials and methods: A total of 150 patients receiving TKIs were retrospectively analyzed. Progression-free survival and OS times were analyzed with the Kaplan–Meier method, and the log‐rank test was used for comparison. Univariable and multivariable Cox regression models evaluated the impact of NLR and PLR on OS of the patients. The receiver operating characteristic curve analysis determined that the optimal cut-off values of NL, and PLR in predicting OS were 2 and 204, respectively. Results: Patient with PLR > 204 had significantly lower median OS time than those with PLR ≤ 204 (14.6 months vs. 31.6 months, P < 0.001). While the univariate analyses showed that both NLR and PLR associated with OS (NLR: P = 0.002; PLR: P < 0.001), PLR, not NLR, was an independent determinant for OS in the multivariate analyses (Hazard Ratio: 2.535, 95% CI: 1.564-4.108, P < 0.001). Additionally, the presence of brain metastases and International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic scoring system were identified as independent prognostic factors for OS (brain metastases: P = 0.040; IMDC: P < 0.001). Conclusion: The PLR is a readily and inexpensively obtained marker, which may predict OS in patients with mRCC treated with TKIs.Key words: NLR, PLR, metastatic renal cell carcinoma, prognosis, tyrosine kinase inhibitors

PDF

___

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: A Cancer Journal for Clinicians 2016; 66 (1): 7-30. doi: 10.3322/ caac.21332
2. Gandaglia G, Ravi P, Abdollah F, Abd-El A-E-RM. Contemporary incidence and mortality rates of kidney cancer in the United States. Canadian Urological Association Journal 2014; 8 (7-8): 247. doi: 10.5489/cuaj.1760
3. Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L et al. Renal cell carcinoma. Nature Reviews Disease Primers 2017; 3: 17009. doi: 10.1038/nrdp.2017.9
4. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents: results from a large, multicenter study. Journal of Clinical Oncology 2009; 27 (34): 5794-5799. doi: 10.1200/JCO.2008.21.4809
5. Kotecha RR, Motzer RJ, Voss MH. Towards individualized therapy for metastatic renal cell carcinoma. Nature Reviews Clinical Oncology 2019; 16 (10): 621-633. doi: 10.1038/s41571- 019-0209-1
6. Webster WS, Lohse CM, Thompson RH, Dong H, Frigola X et al. Mononuclear cell infiltration in clear‐cell renal cell carcinoma independently predicts patient survival. Cancer 2006; 107 (1): 46-53. doi: 10.1002/cncr.21951
7. Şenbabaoğlu Y, Gejman RS, Winer AG, Liu M, Van Allen EM et al. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biology 2016; 17 (1): 1-25. doi: 10.1186/s13059-016- 1092-z
8. Gunduz S, Mutlu H, Tural D, Yıldız Ö, Uysal M et al. Platelet to lymphocyte ratio as a new prognostic for patients with metastatic renal cell cancer. Asia-Pacific Journal of Clinical Oncology 2015; 11 (4): 288-292. doi: 10.1111/ajco.12358
9. Park TJ, Cho YH, Chung HS, Hwang EC, Jung S-H et al. Prognostic significance of platelet–lymphocyte ratio in patients receiving first-line tyrosine kinase inhibitors for metastatic renal cell cancer. SpringerPlus 2016; 5 (1): 1889. doi: 10.1186/ s40064-016-3592-4
10. Keizman D, Ish-Shalom M, Huang P, Eisenberger MA, Pili R et al. The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. European Journal of Cancer 2012; 48 (2): 202- 208. doi: 10.1016/j.ejca.2011.09.001
11. Pichler M, Hutterer G, Stoeckigt C, Chromecki T, Stojakovic T et al. Validation of the pre-treatment neutrophil–lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients. British Journal of Cancer 2013; 108 (4): 901-907. doi: 10.1038/bjc.2013.28
12. Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2016; 27 (suppl_5): v58-v68. doi: 10.1093/annonc/mdw328
13. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140 (6): 883-899. doi: 10.1016/j. cell.2010.01.025
14. Santoni M, Massari F, Amantini C, Nabissi M, Maines F et al. Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. Cancer Immunology, Immunotherapy 2013; 62 (12): 1757-1768. doi: 10.1007/s00262-013-1487-6
15. Zahorec R. Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill. Bratislavske Lekarske Listy 2001; 102 (1): 5-14.
16. Stehle F, Leisz S, Schulz K, Schwurack N, Weber N et al. VHLdependent alterations in the secretome of renal cell carcinoma: Association with immune cell response? Oncotarget 2015; 6 (41): 43420. doi: 10.18632/oncotarget.5560
17. Gunduz S, Mutlu H, Uysal M, Coskun HS, Bozcuk H. Prognostic value of hematologic parameters in patients with metastatic renal cell carcinoma using tyrosine kinase inhibitors. Asian Pacific Journal of Cancer Prevention 2014; 15 (8): 3801-3804. doi: 10.7314/apjcp.2014.15.8.3801
18. Keizman D, Gottfried M, Ish-Shalom M, Maimon N, Peer A et al. Active smoking may negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treated with sunitinib. The Oncologist 2014; 19 (1): 51. doi: 10.1634/theoncologist.2012-0335
19. Chrom P, Stec R, Semeniuk-Wojtas A, Bodnar L, Spencer NJ et al. Fuhrman grade and neutrophil-to-lymphocyte ratio influence on survival in patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors. Clinical Genitourinary Cancer 2016; 14 (5): 457-464. doi: 10.1016/j. clgc.2016.02.005
20. Wang YQ, Zhi QJ, Wang XY, Yue DS, Li K et al. Prognostic value of combined platelet, fibrinogen, neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in patients with lung adenosquamous cancer. Oncology Letters 2017; 14 (4): 4331- 4338. doi: 10.3892/ol.2017.6660
21. Kwon H-C, Kim SH, Oh SY, Lee S, Lee JH et al. Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer. Biomarkers 2012; 17 (3): 216-222. doi: 10.3109/1354750X.2012.656705
22. Krenn-Pilko S, Langsenlehner U, Thurner E, Stojakovic T, Pichler M et al. The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients. British Journal of Cancer 2014; 110 (10): 2524-2530. doi: 10.1038/ bjc.2014.163
23. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Molecular Cancer Research 2006; 4 (4): 221- 233. doi: 10.1158/1541-7786.MCR-05-0261
24. Xi H, Gao Y-H, Han D-Y, Li Q-Y, Feng L-J et al. Hypoxia inducible factor-1α suppresses Peroxiredoxin 3 expression to promote proliferation of CCRCC cells. FEBS Letters 2014; 588 (18): 3390-3394. doi: 10.1016/j.febslet.2014.07.030
25. De Vivar Chevez AR, Finke J, Bukowski R. The role of inflammation in kidney cancer. Advances in Experimental Medicine and Biology 2014; 816: 197-234. doi: 10.1007/978-3-0348- 0837-8_9
26. Palazon A, Goldrath AW, Nizet V, Johnson RS. HIF transcription factors, inflammation, and immunity. Immunity 2014; 41 (4): 518-528. doi: 10.1016/j.immuni.2014.09.008
27. An H, Zhu Y, Xie H, Liu Y, Liu W et al. Increased expression of interleukin-8 is an independent indicator of poor prognosis in clear-cell renal cell carcinoma. Tumor Biology 2016; 37 (4): 4523-4529. doi: 10.1007/s13277-015-4158-8
28. Gu L, Li H, Gao Y, Ma X, Chen L et al. The association of platelet count with clinicopathological significance and prognosis in renal cell carcinoma: a systematic review and metaanalysis. Plos One 2015; 10 (5): e0125538. doi: 10.1371/journal. pone.0125538
29. Verheul HM, Jorna AS, Hoekman K, Broxterman HJ, Gebbink MF et al. Vascular endothelial growth factor–stimulated endothelial cells promote adhesion and activation of platelets. Blood 2000; 96 (13): 4216-4221.
30. Ramsey S, Lamb GW, Aitchison M, McMillan DC. Prospective study of the relationship between the systemic inflammatory response, prognostic scoring systems and relapse‐free and cancer‐specific survival in patients undergoing potentially curative resection for renal cancer. BJU International 2008; 101 (8): 959-963. doi: 10.1111/j.1464-410X.2007.07363.x
31. Bromwich E, McArdle P, Canna K, McMillan D, McNicol A et al. The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer. British Journal of Cancer 2003; 89 (10): 1906-1908. doi: 10.1038/sj.bjc.6601400
32. Baxevanis CN, Dedoussis GV, Papadopoulos NG, Missitzis I, Stathopoulos GP et al. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer. Cancer 1994; 74 (4): 1275-1282. doi: 10.1002/1097-0142(19940815)74:4<1275::aidcncr2820740416>3.0.co;2-q
33. Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M et al. Tumour‐infiltrating T‐cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. The Journal of Pathology 2010; 222 (4): 350-366. doi: 10.1002/ path.2774